-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 JQr2LFhrAnpVhIVTbeXIaNCtOTqaWeIQdURFjZxnm/jXmWjdEBIcoDNZHgP0+Uk9
 cntvEZLggj0x1M76/0eOWw==

<SEC-DOCUMENT>0001157523-08-002753.txt : 20080407
<SEC-HEADER>0001157523-08-002753.hdr.sgml : 20080407
<ACCEPTANCE-DATETIME>20080407084604
ACCESSION NUMBER:		0001157523-08-002753
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20080404
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Material Modifications to Rights of Security Holders
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20080407
DATE AS OF CHANGE:		20080407

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANIKA THERAPEUTICS INC
		CENTRAL INDEX KEY:			0000898437
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				043145961
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14027
		FILM NUMBER:		08741839

	BUSINESS ADDRESS:	
		STREET 1:		236 WEST CUMMINGS PARK
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801
		BUSINESS PHONE:		6179326616

	MAIL ADDRESS:	
		STREET 1:		236 WEST CUMMINGS PARK
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANIKA RESEARCH INC
		DATE OF NAME CHANGE:	19930309
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a5650961.htm
<DESCRIPTION>ANIKA THERAPEUTICS, INC. 8-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2008 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 10pt">
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 12pt">UNITED STATES</font><font style="font-family: Times New Roman; font-size: 12pt"><br style="font-family: Times New Roman; font-size: 12pt"></font><font style="font-family: Times New Roman; font-size: 12pt">SECURITIES
      AND EXCHANGE COMMISSION</font><br><font style="font-family: Times New Roman; font-size: 10pt">Washington,
      D.C. 20549</font><br><br><font style="font-family: Times New Roman; font-size: 12pt"><b>FORM
      8-K</b></font>
    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 12pt"><b>Current
      Report Pursuant</b></font><br><font style="font-family: Times New Roman; font-size: 12pt">to
      Section 13 or 15(D) of the</font><br><font style="font-family: Times New Roman; font-size: 12pt">Securities
      Exchange Act of 1934</font>
    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 10pt">Date of
      Report (Date of earliest event reported): </font><br><font style="font-family: Times New Roman; font-size: 10pt"><b>April
      4, 2008</b></font><font style="font-family: Times New Roman; font-size: 10pt"><br style="font-family: Times New Roman; font-size: 10pt"></font><br>
    </p>
    <p style="text-align: center">
      <font style="font-size: 14pt"><u>Anika Therapeutics, Inc.</u></font><font style="font-size: 14pt">
      </font><br><font style="font-family: Times New Roman; font-size: 10pt">(Exact
      name of registrant as specified in its charter)</font><br><font style="font-family: Times New Roman"><b>______________</b></font><br>
    </p>
    <table cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 10pt; margin-bottom: 10.0px">
      <tr>
        <td style="text-align: center; padding-left: 0.0px; width: 33%; border-bottom: solid black 1.0pt" valign="bottom">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Massachusetts
          </p>
        </td>
        <td style="text-align: center; padding-left: 0.0px; white-space: nowrap; width: 34%; padding-right: 0.0px; border-bottom: solid black 1.0pt" valign="bottom">
          <p style="margin-top: 0px; margin-bottom: 0px">
            000-21326
          </p>
        </td>
        <td style="text-align: center; padding-left: 0.0px; white-space: nowrap; width: 33%; padding-right: 0.0px; border-bottom: solid black 1.0pt" valign="bottom">
          <p style="margin-top: 0px; margin-bottom: 0px">
            04-314-5961
          </p>
        </td>
      </tr>
      <tr>
        <td style="text-align: center; padding-left: 0.0px; width: 33%" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            (State or other jurisdiction
          </p>
          <p style="margin-top: 0px; margin-bottom: 0px">
            of incorporation)
          </p>
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td style="text-align: center; padding-left: 0.0px; width: 34%" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Commission file number
          </p>
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td style="text-align: center; padding-left: 0.0px; width: 33%" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            (IRS employer<br>identification no.)
          </p>
        </td>
      </tr>
    </table>
    <table cellspacing="0" style="font-family: Times New Roman; width: 100%; font-size: 10pt; margin-bottom: 10.0px">
      <tr>
        <td style="text-align: center; padding-left: 0.0px; border-bottom: solid black 1.0pt" valign="bottom">
          <p style="margin-top: 0px; margin-bottom: 0px">
            32 Wiggins Avenue, Bedford, Massachusetts&#160;&#160;01730
          </p>
        </td>
      </tr>
      <tr>
        <td style="text-align: center; padding-left: 0.0px" valign="bottom">
          <p style="margin-top: 0px; margin-bottom: 0px">
            (Address of principal executive offices) (Zip code)
          </p>
        </td>
      </tr>
    </table>
    <p style="text-align: center">
      <br>
      Registrant&#8217;s telephone number, including area code: <u>(781)
      457-9000</u>
    </p>
    <p style="text-align: center">

    </p>
    <p>
      <font style="font-family: Times New Roman; font-size: 10pt">Check the
      appropriate box below if the Form 8-K filing is intended to
      simultaneously satisfy the filing obligation of the registrant under any
      of the following provisions:</font>
    </p>
    <p>
      <font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font>
      <font style="font-family: Times New Roman; font-size: 10pt">Written
      communications pursuant to Rule 425 under the Securities Act (17 CFR
      230.425)</font>
    </p>
    <p>
      <font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font>
      <font style="font-family: Times New Roman; font-size: 10pt">Soliciting
      material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)</font>
    </p>
    <p>
      <font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font>
      <font style="font-family: Times New Roman; font-size: 10pt">Pre-commencement
      communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
      240.14d-2(b))</font>
    </p>
    <p>
      <font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font>
      <font style="font-family: Times New Roman; font-size: 10pt">Pre-commencement
      communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
      240.13e-4(c))</font>
    </p>
    <div style="margin-left: 0pt; margin-right: 0pt; width: 100%; text-indent: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <p>
      <font style="font-family: Times New Roman; font-size: 10pt"><b>Item
      1.01&#160;&#160;&#160;&#160;&#160;Entry into a Material Definitive Agreement.</b></font><br>
    </p>
    <p style="text-align: justify; text-indent: 30.0px">
      On April 4, 2008 the Board of Directors of Anika Therapeutics, Inc. (the
      &#8220;Company&#8221;) adopted a shareholder rights plan, as set forth in the
      Shareholder Rights Agreement, dated April&#160;7, 2008, between the Company
      and American Stock Transfer and Trust Company, as Rights Agent (the
      &#8220;Rights Agreement&#8221;). The following description of the terms of the
      Rights Agreement does not purport to be complete and is qualified in its
      entirety by reference to the Rights Agreement which is attached hereto
      as an exhibit and is incorporated herein by reference.
    </p>
    <p style="text-align: justify; text-indent: 30.0px">
      Pursuant to the terms of the Rights Agreement, the Board of Directors
      declared a dividend distribution of one Preferred Stock Purchase Right
      (a &#8220;Right&#8221;) for each outstanding share of Common Stock of the Company
      (the &#8220;Common Stock&#8221;) to shareholders of record as of the close of
      business on April 8, 2008 (the &#8220;Record Date&#8221;). In addition, one Right
      will automatically attach to each share of Common Stock issued between
      the Record Date and the Distribution Date (as hereinafter defined). Each
      Right entitles the registered holder thereof to purchase from the
      Company a unit consisting of one ten-thousandth of a share (a &#8220;Unit&#8221;) of
      Series B Junior Participating Cumulative Preferred Stock, par value
      $0.01 per share, of the Company (the &#8220;Preferred Stock&#8221;) at a cash
      exercise price of $75.00 per Unit (the &#8220;Exercise Price&#8221;), subject to
      adjustment, under certain conditions specified in the Rights Agreement
      and summarized below.
    </p>
    <p style="text-align: justify; text-indent: 30.0px">
      Initially, the Rights are not exercisable and are attached to and trade
      with all shares of Common Stock outstanding as of, and issued subsequent
      to, the Record Date. The Rights will separate from the Common Stock and
      will become exercisable upon the earlier of (i) the close of business on
      the tenth calendar day following the first public announcement that a
      person or group of affiliated or associated persons (an &#8220;Acquiring
      Person&#8221;) has acquired beneficial ownership of 15% or more of the
      outstanding shares of Common Stock, other than as a result of
      repurchases of stock by the Company or certain inadvertent actions by a
      shareholder (the date of said announcement being referred to as the
      &#8220;Stock Acquisition Date&#8221;), or (ii) the close of business on the tenth
      business day (or such later day as the Board of Directors may determine)
      following the commencement of a tender offer or exchange offer that
      could result upon its consummation in a person or group becoming the
      beneficial owner of 15% or more of the outstanding shares of Common
      Stock (the earlier of such dates being herein referred to as the
      &#8220;Distribution Date&#8221;).
    </p>
    <p style="text-align: justify; text-indent: 30.0px">
      Notwithstanding the foregoing, with respect to any person who
      beneficially owns (for purposes of the Rights Agreement) 15% or more of
      the outstanding shares of Common Stock as of 12:01 a.m. EST on April 7,
      2008 (such person being referred to in the Rights Agreement as a
      &#8220;Grandfathered Person&#8221;), the Distribution Date will not occur unless
      such Grandfathered Person has acquired beneficial ownership of shares of
      Common Stock representing an additional &#189;% of the outstanding shares of
      Common Stock.
    </p>
    <p style="text-align: justify; text-indent: 30.0px">
      In the event that a Stock Acquisition Date occurs, proper provision will
      be made so that each holder of a Right (other than an Acquiring Person
      or its associates or affiliates, whose Rights shall become null and
      void) will thereafter have the right to receive upon exercise, in lieu
      of a number of Units of Preferred Stock, that number of shares of Common
      Stock of the Company (or, in certain circumstances, including if there
      are insufficient shares of Common Stock to permit the exercise in full
      of the Rights, Units of Preferred Stock, other securities, cash or
      property, or any combination of the foregoing) having a market value of
      two times the exercise price of the Right (such right being referred to
      as the &#8220;Subscription Right&#8221;). In the event that, at any time following
      the Stock Acquisition Date, (i) the Company consolidates with, or merges
      with and into, any other person, and the Company is not the continuing
      or surviving corporation, (ii) any person consolidates with the Company,
      or merges with and into the Company and the Company is the continuing or
      surviving corporation of such merger and, in connection with such
      merger, all or part of the shares of Common Stock are changed into or
      exchanged for stock or other securities of any other person or cash or
      any other property, or (iii) 50% or more of the Company&#8217;s assets or
      earning power is sold, mortgaged or otherwise transferred, each holder
      of a Right (other than an Acquiring Person or its associates or
      affiliates, whose Rights shall become null and void) will thereafter
      have the right to receive, upon exercise, common stock of the acquiring
      company having a market value equal to two times the exercise price of
      the Right (such right being referred to as the &#8220;Merger Right&#8221;). The
      holder of a Right will continue to have the Merger Right whether or not
      such holder has exercised the Subscription Right. Rights that are or
      were beneficially owned by an Acquiring Person may (under certain
      circumstances specified in the Rights Agreement) become null and void.
    </p>
    <p style="font-family: Times New Roman; text-indent: 30.0px; font-size: 10pt">

    </p>
    <p style="text-align: center">
      2
    </p>
    <div style="margin-left: 0pt; margin-right: 0pt; width: 100%; text-indent: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="font-family: Times New Roman; text-indent: 30.0px; font-size: 10pt">

    </p>
    <p style="text-align: justify; text-indent: 30.0px">
      The Rights may be redeemed in whole, but not in part, at a price of
      $0.01 per Right (payable in cash, Common Stock or other consideration
      deemed appropriate by the Board of Directors) by the Board of Directors
      only until the earlier of (i) the time at which any person becomes an
      Acquiring Person or (ii) the expiration date of the Rights Agreement.
      Immediately upon the action of the Board of Directors ordering
      redemption of the Rights, the Rights will terminate and thereafter the
      only right of the holders of Rights will be to receive the redemption
      price.
    </p>
    <p style="text-align: justify; text-indent: 30.0px">
      The Rights Agreement may be amended by the Board of Directors in its
      sole discretion until the time at which any person becomes an Acquiring
      Person. After such time the Board of Directors may, subject to certain
      limitations set forth in the Rights Agreement, amend the Rights
      Agreement only to cure any ambiguity, defect or inconsistency, to
      shorten or lengthen any time period, or to make changes that do not
      adversely affect the interests of Rights holders (excluding the
      interests of an Acquiring Person or its associates or affiliates). In
      addition, the Board of Directors may at any time prior to the time at
      which any person becomes an Acquiring Person, amend the Rights Agreement
      to lower the threshold at which a person becomes an Acquiring Person to
      not less than the greater of (i) the sum of .001% and the largest
      percentage of the outstanding Common Stock then owned by any person and
      (ii) 10%.
    </p>
    <p style="text-align: justify; text-indent: 30.0px">
      Until a Right is exercised, the holder will have no rights as a
      stockholder of the Company (beyond those as an existing stockholder),
      including the right to vote or to receive dividends. While the
      distribution of the Rights will not be taxable to stockholders or to the
      Company, stockholders may, depending upon the circumstances, recognize
      taxable income in the event that the Rights become exercisable for
      Units, other securities of the Company, other consideration or for
      common stock of an acquiring company.
    </p>
    <p style="text-align: justify; text-indent: 30.0px">

    </p>
    <p style="text-align: center">
      3
    </p>
    <div style="margin-left: 0pt; margin-right: 0pt; width: 100%; text-indent: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="font-family: Times New Roman; text-indent: 30.0px; font-size: 10pt">

    </p>
    <p style="font-family: Times New Roman; text-indent: 30.0px; font-size: 10pt">
      The Rights are not exercisable until the Distribution Date and will
      expire at the close of business on April 8, 2018 (the &#8220;Expiration
      Date&#8221;), unless previously redeemed or exchanged by the Company as
      described below.
    </p>
    <p>
      <br>
      <b>Item 3.03&#160;&#160;&#160;&#160;&#160;Material Modification to Rights of Security Holders.</b><br>
    </p>
    <p>
      Please see the disclosure set forth under Item 1.01, which is
      incorporated by reference into this Item 3.03.
    </p>
    <p>
      <br>
      <b>Item 9.01&#160;&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</b><br>
    </p>
    <table cellspacing="0" style="font-family: Times New Roman; width: 100%; font-size: 10pt; margin-bottom: 10.0px">
      <tr>
        <td style="text-align: left; padding-left: 0.0px; width: 3%" valign="top">
          (d)
        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 10%" valign="top">
          Exhibits
        </td>
        <td style="width: 87%">

        </td>
      </tr>
      <tr>
        <td colspan="3">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 0.0px; width: 3%" valign="top">

        </td>
        <td style="text-align: left; padding-left: 0.0px; white-space: nowrap; width: 10%; padding-right: 0.0px" valign="top">
          3.1
        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 87%" valign="top">
          Amended and Restated Certificate of Vote of Directors Establishing a
          Series of Preferred Stock of Anika Therapeutics, Inc. classifying
          and designating the Series B Junior Participating Cumulative
          Preferred Stock, filed as an exhibit to the Company&#8217;s Registration
          Statement on Form 8-A on April 7, 2008.
        </td>
      </tr>
      <tr>
        <td colspan="3">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 0.0px; width: 3%" valign="top">

        </td>
        <td style="text-align: left; padding-left: 0.0px; white-space: nowrap; width: 10%; padding-right: 0.0px" valign="top">
          4.1
        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 87%" valign="top">
          Shareholder Rights Agreement, dated as of April 7, 2008 between
          Anika Therapeutics, Inc. and American Stock Transfer and Trust
          Company, as Rights Agent, filed as an exhibit to the Company&#8217;s
          Registration Statement on Form 8-A on April 7, 2008.
        </td>
      </tr>
      <tr>
        <td colspan="3">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 0.0px; width: 3%" valign="top">

        </td>
        <td style="text-align: left; padding-left: 0.0px; white-space: nowrap; width: 10%; padding-right: 0.0px" valign="top">
          99.1
        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 87%" valign="top">
          Press Release issued by Anika Therapeutics, Inc. dated April 4, 2008.
        </td>
      </tr>
    </table>
    <p style="white-space: nowrap">

    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 10pt">4</font><font style="font-family: Times New Roman; font-size: 10pt"><br style="font-family: Times New Roman; font-size: 10pt"></font>
    </p>
    <div style="margin-left: 0pt; margin-right: 0pt; width: 100%; text-indent: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 10pt">SIGNATURE</font>
    </p>
    <p style="font-family: Times New Roman; text-indent: 30.0px; font-size: 10pt">
      <font style="font-family: Times New Roman; font-size: 10pt">Pursuant to
      the requirements of the Securities Exchange Act of 1934, the registrant
      has duly caused this report to be signed on its behalf by the
      undersigned hereunto duly authorized.</font>
    </p>
    <table cellspacing="0" style="font-family: Times New Roman; width: 100%; font-size: 10pt; margin-bottom: 10.0px">
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 43%">

        </td>
        <td style="text-align: left; padding-left: 0.0px" colspan="2" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            ANIKA THERAPEUTICS, INC.
          </p>
        </td>
        <td style="width: 15%">

        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 43%">

        </td>
        <td style="text-align: left; padding-left: 0.0px" colspan="2" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 15%">

        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 0.0px; width: 5%; padding-bottom: 2.0px" valign="top">
          Date:
        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 43%; padding-bottom: 2.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            April 7, 2008
          </p>
        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 7%; padding-bottom: 2.0px" valign="top">
          By:
        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 30%; border-bottom: solid black 1.0pt" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            /s/ Kevin W. Quinlan
          </p>
        </td>
        <td style="width: 15%">

        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 43%">

        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 7%" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Name:
          </p>
        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 30%" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Kevin W. Quinlan
          </p>
        </td>
        <td style="width: 15%">

        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 43%">

        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 7%" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Title:
          </p>
        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 30%" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Chief Financial Officer
          </p>
        </td>
        <td style="width: 15%">

        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 43%">

        </td>
        <td style="width: 7%">

        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 30%" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 15%">

        </td>
      </tr>
    </table>
    <p>

    </p>
    <p style="text-align: center">
      5
    </p>
    <div style="margin-left: 0pt; margin-right: 0pt; width: 100%; text-indent: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: left">
      <font style="font-family: Times New Roman; font-size: 10pt"><b>EXHIBIT
      INDEX </b></font>
    </p>
    <table cellspacing="0" style="font-family: Times New Roman; width: 100%; font-size: 10pt; margin-bottom: 10.0px">
      <tr>
        <td style="text-align: left; padding-left: 0.0px; width: 3%" valign="top">
          &#160;
        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 10%" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <u>Exhibit No.</u>
          </p>
        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 87%" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <u>Description</u>
          </p>
        </td>
      </tr>
      <tr>
        <td colspan="3">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 0.0px; width: 3%" valign="top">

        </td>
        <td style="text-align: left; padding-left: 0.0px; white-space: nowrap; width: 10%; padding-right: 0.0px" valign="top">
          3.1
        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 87%" valign="top">
          Amended and Restated Certificate of Vote of Directors Establishing a
          Series of Preferred Stock of Anika Therapeutics, Inc. classifying
          and designating the Series B Junior Participating Cumulative
          Preferred Stock, filed as an exhibit to the Company&#8217;s Registration
          Statement on Form 8-A on April 7, 2008.
        </td>
      </tr>
      <tr>
        <td colspan="3">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 0.0px; width: 3%" valign="top">

        </td>
        <td style="text-align: left; padding-left: 0.0px; white-space: nowrap; width: 10%; padding-right: 0.0px" valign="top">
          4.1
        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 87%" valign="top">
          Shareholder Rights Agreement, dated as of April 7, 2008 between
          Anika Therapeutics, Inc. and American Stock Transfer and Trust
          Company, as Rights Agent, filed as an exhibit to the Company&#8217;s
          Registration Statement on Form 8-A on April 7, 2008.
        </td>
      </tr>
      <tr>
        <td colspan="3">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 0.0px; width: 3%" valign="top">

        </td>
        <td style="text-align: left; padding-left: 0.0px; white-space: nowrap; width: 10%; padding-right: 0.0px" valign="top">
          99.1
        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 87%" valign="top">
          Press Release issued by Anika Therapeutics, Inc. dated April 4, 2008.
        </td>
      </tr>
    </table>
    <p style="white-space: nowrap">

    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 10pt">6</font>
    </p>
    <p style="text-align: left">

    </p>
  </body>
</html>
<!--<!DOCTYPE html
     PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN"
     "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">-->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a5650961ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2008 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 8pt">
    <p style="text-align: right">
      <b>Exhibit 99.1</b>
    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 12pt"><b>Anika
      Therapeutics, Inc. Renews Shareholder Rights Plan</b></font>
    </p>
    <p>
      BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (NASDAQ: ANIK)
      announced today that its Board of Directors has renewed its Shareholder
      Rights Plan. The renewed plan is similar to the original plan that had
      been in existence for 10 years and is due to expire soon. Shareholder
      rights plans are designed to strengthen the ability of a board of
      directors to protect a company&#8217;s stockholders against abusive or
      coercive takeover tactics that are not in the best interests of the
      company and its stockholders.
    </p>
    <p>
      Details of the plan can be found in Anika&#8217;s Form 8-K, which will be
      filed shortly with the Securities and Exchange Commission.
    </p>
    <p>
      <b>About Anika Therapeutics, Inc.</b>
    </p>
    <p>
      Headquartered in Bedford, Mass., Anika Therapeutics, Inc. develops,
      manufactures and commercializes therapeutic products for tissue
      protection, healing and repair. These products are based on hyaluronic
      acid (HA), a naturally occurring, biocompatible polymer found throughout
      the body. Anika&#8217;s products include ORTHOVISC<sup>&#174;</sup>, a
      treatment for osteoarthritis of the knee available internationally and
      marketed in the U.S. by DePuy Mitek; HYVISC<sup>&#174;</sup>, a
      treatment for equine osteoarthritis marketed in the U.S. by Boehringer
      Ingelheim Vetmedica, Inc.; the ELEVESS<sup>&#8482;</sup> family of
      aesthetic dermatology products for facial wrinkles, scar remediation and
      lip augmentation; AMVISC<sup>&#174;</sup>, AMVISC<sup>&#174;</sup> Plus,
      STAARVISC&#8482;-II and Shellgel&#8482; injectable viscoelastic HA products for
      ophthalmic surgery; INCERT<sup>&#174;</sup>, an HA-based anti-adhesive
      for surgical applications; ORTHOVISC<sup>&#174; </sup><i>Mini</i> a
      treatment for osteoarthritis targeting small joints and available in
      Europe, MONOVISC<sup>&#8482; </sup>a single-injection osteoarthritis
      product based on our proprietary cross-linking technology and scheduled
      to launch in Europe mid year 2008,<sup> </sup>and next generation
      products for joint health and aesthetic dermatology based on the
      Company&#8217;s proprietary, chemically modified HA.
    </p>
    <p>

    </p>
    <p>
      CONTACT:<br>Anika Therapeutics, Inc.<br>Charles H. Sherwood, Ph.D.,
      781-457-9000<br>CEO<br>or<br>Kevin W. Quinlan, 781-457-9000<br>CFO<br>
    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
